MIRM Stock Analysis Today
Updated Nov 12, 2026 · trends, key levels, insider activity and news
Is MIRM bullish or bearish today?
Daily trend: Downtrend (confirmed) — turns up above $104.66
SEPT signal: Distribution · Bullish
Research grade: B+ · fair value $155.00 (+63.8%)
MIRM trend by timeframe
| Daily | Downtrend (confirmed) |
|---|---|
| 4 hour | Bullish |
| 1 hour | Descending Triangle |
| 15 min | Ascending Triangle |
| 5 min | Ascending Triangle |
Trends are calculated from price structure and update during market hours.
MIRM support and resistance levels
Resistance (above)
$93.574 touches
$98.9710 touches
$103.284 touches
Support (below)
$85.847 touches
$80.244 touches
$73.823 touches
Upside zones: $101.06 / $103.09 / $105.12
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 1330-day net
-$1.8MHedge fund holders
289Latest MIRM news and filings
- AnalystBenzinga
Citigroup keeps Buy rating on Mirum Pharmaceuticals, lifts target to $194
Citigroup reiterated its Buy rating on Mirum Pharmaceuticals and raised its price target to $194. The update reflects the analyst's view on the stock.
- ProductFiscal.ai
Mirum Pharmaceuticals says AZURE-4 Phase 3 study met its primary endpoint
Mirum Pharmaceuticals reported that the Phase 3 AZURE-4 study reached its main goal. The company did not give further details in the announcement.
- NewsFiscal.ai
Christopher Peetz, chief executive of Mirum Pharmaceuticals, offloads $1.8 million in stock
The head of Mirum Pharmaceuticals disposed of $1.8 million worth of company stock. A filing shows the chief executive's share sale.
- AnalystBenzinga
Leerink Partners keeps Outperform rating on Mirum Pharmaceuticals, cuts target to $140
Leerink Partners kept its Outperform rating on Mirum Pharmaceuticals while reducing its price target to $140. The change reflects the firm's updated view on the stock.
Live MIRM chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Why did MIRM stock move on Oct 26, 2026?
Oct 26, 2026: Mirum Pharmaceuticals shares rose 2.57% to close at $83.47 after the company announced that its Phase 2 PROGRESS trial of ATEBRIOZ in children with FOP met its goals, with positive results reported. The company also released Cohort 2 results from the pivotal PROGRESS study, reinforcing the drug's potential in a late-stage setting.
Is MIRM bullish or bearish today?
MIRM daily trend: Downtrend (confirmed) — turns up above $104.66. SEPT signal: Distribution (Bullish). Updated Nov 12, 2026.
What is MIRM's trend on each timeframe?
Daily: Downtrend (confirmed); 4 hour: Bullish; 1 hour: Descending Triangle; 15 min: Ascending Triangle; 5 min: Ascending Triangle.
What are MIRM support and resistance levels?
Support: $85.84, $80.24, $73.82. Resistance: $93.57, $98.97, $103.28. Last price $93.35.
Are insiders buying or selling MIRM?
Insider signal: Sell. Last 30 days: 0 buys, 13 sells, net -$1.8M. 289 hedge funds hold MIRM.
What is the latest news on MIRM?
Nov 11, 2026: Citigroup keeps Buy rating on Mirum Pharmaceuticals, lifts target to $194 · Nov 10, 2026: Mirum Pharmaceuticals says AZURE-4 Phase 3 study met its primary endpoint · Nov 5, 2026: Christopher Peetz, chief executive of Mirum Pharmaceuticals, offloads $1.8 million in stock